Jennifer Adema, PharmD, MBA (@JAdemaPharmD) describes remdesivir’s mechanism of action against SARS-CoV-2, identifies optimal adult patient populations for remdesivir and outlines future directions for remdesivir in COVID-19 treatment.
For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!
You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.